Vivatides Therapeutics Funding: $54M Raised, Series A (2026)
Vivatides Therapeutics has raised $54M in total funding. Latest round: Series A. Backed by Qiming Venture Partners, Highlight Capital, TF Capital.
Vivatides Therapeutics funding overview
Vivatides Therapeutics has raised $54M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in April 2026. The round record for Vivatides Therapeutics runs through 2026; nothing later has been disclosed. Investors on record include Qiming Venture Partners, Highlight Capital, TF Capital, Apricot Capital. 4 distinct backers are named across the disclosed rounds.
Vivatides Therapeutics at a glance
Total raised
$54M
Latest round
Series A
Latest round date
April 2026
Notable investors
Qiming Venture Partners, Highlight Capital, TF Capital, Apricot Capital
Frequently asked about Vivatides Therapeutics funding
How much has Vivatides Therapeutics raised?
Vivatides Therapeutics has raised $54M in total disclosed funding across the rounds on record.
Who has invested in Vivatides Therapeutics?
Qiming Venture Partners, Highlight Capital, TF Capital, Apricot Capital are named among the investors backing Vivatides Therapeutics.
What was the latest Vivatides Therapeutics funding round?
The most recent disclosed round is a Series A, announced in April 2026.
Where is Vivatides Therapeutics based?
No headquarters location is disclosed for Vivatides Therapeutics.
When did Vivatides Therapeutics last raise?
The last disclosed Vivatides Therapeutics round closed in April 2026 at Series A.
Vivatides Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies below to benchmark round size and investor mix.
